Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.

Savickiene J, Treigyte G, Jazdauskaite A, Borutinskaite VV, Navakauskiene R.

Cell Biol Int. 2012 Nov 1;36(11):1067-78. doi: 10.1042/CBI20110649.

PMID:
22845560
2.

Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells.

Savickiene J, Treigyte G, Borutinskaite VV, Navakauskiene R.

Cell Mol Biol Lett. 2012 Dec;17(4):501-25. Epub 2012 Jul 20.

PMID:
22820861
3.

C/EBPα and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling.

Savickiene J, Treigyte G, Vistartaite G, Tunaitis V, Magnusson KE, Navakauskiene R.

Differentiation. 2011 Jan;81(1):57-67. doi: 10.1016/j.diff.2010.08.003. Epub 2010 Sep 22.

PMID:
20864248
4.

Epigenetic changes during hematopoietic cell granulocytic differentiation--comparative analysis of primary CD34+ cells, KG1 myeloid cells and mature neutrophils.

Navakauskienė R, Borutinskaitė VV, Treigytė G, Savickienė J, Matuzevičius D, Navakauskas D, Magnusson KE.

BMC Cell Biol. 2014 Jan 20;15:4. doi: 10.1186/1471-2121-15-4.

5.

Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.

Savickiene J, Treigyte G, Magnusson KE, Navakauskiene R.

Ann N Y Acad Sci. 2009 Aug;1171:321-33. doi: 10.1111/j.1749-6632.2009.04718.x.

PMID:
19723072
6.

The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.

Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, Navakauskiene R.

Eur J Pharmacol. 2006 Nov 7;549(1-3):9-18. Epub 2006 Aug 15.

PMID:
16978604
7.
8.

Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.

Valiuliene G, Stirblyte I, Cicenaite D, Kaupinis A, Valius M, Navakauskiene R.

J Cell Mol Med. 2015 Jul;19(7):1742-55. doi: 10.1111/jcmm.12550. Epub 2015 Apr 11.

9.

Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells.

Savickiene J, Treigyte G, Jonusiene V, Bruzaite R, Borutinskaite VV, Navakauskiene R.

Mol Cell Biochem. 2012 Jan;359(1-2):245-61. doi: 10.1007/s11010-011-1019-7. Epub 2011 Aug 13.

PMID:
21842375
11.

Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.

Savickiene J, Treigyte G, Valiuliene G, Stirblyte I, Navakauskiene R.

Anticancer Drugs. 2014 Sep;25(8):938-49. doi: 10.1097/CAD.0000000000000122.

PMID:
24800886
12.
13.

Effects of DNMT1 and HDAC inhibitors on gene-specific methylation reprogramming during porcine somatic cell nuclear transfer.

Xu W, Li Z, Yu B, He X, Shi J, Zhou R, Liu D, Wu Z.

PLoS One. 2013 May 31;8(5):e64705. doi: 10.1371/journal.pone.0064705. Print 2013.

15.

Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.

Borutinskaite VV, Magnusson KE, Navakauskiene R.

Mol Biol Rep. 2012 Dec;39(12):10179-86. doi: 10.1007/s11033-012-1892-5. Epub 2012 Sep 26.

PMID:
23007576
16.

Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines.

Ou JN, Torrisani J, Unterberger A, Provençal N, Shikimi K, Karimi M, Ekström TJ, Szyf M.

Biochem Pharmacol. 2007 May 1;73(9):1297-307. Epub 2007 Jan 5.

PMID:
17276411
18.

Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.

Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M, McNamara S, Miller WH Jr, Lo Coco F, Pelicci PG, Nervi C.

Oncogene. 2005 Mar 10;24(11):1820-30.

PMID:
15688037
19.

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

Zhu WG, Otterson GA.

Curr Med Chem Anticancer Agents. 2003 May;3(3):187-99. Review.

PMID:
12769777
20.

Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.

Feng D, Wu J, Tian Y, Zhou H, Zhou Y, Hu W, Zhao W, Wei H, Ling B, Ma C.

PLoS One. 2013 Nov 19;8(11):e80657. doi: 10.1371/journal.pone.0080657. eCollection 2013.

Supplemental Content

Support Center